Table 3

Changes in the BCVA and other parameters before and after intravitreal injection of aflibercept

 Type 1 PCVType 2 PCV
Initial*3 months*p Value†Initial*3 months*p Value†
BCVA (logMAR)0.76±0.410.39±0.360.0010.62±0.300.54±0.340.092
Largest polyp size (μm)263.5±104.340.7±55.70.002240.1±78.7135.2±136.70.006
Largest PED height (μm)438.8±299.5190.1±161.10.001313.1±174.5188.5±119.90.002
CMT (μm)461.2±102.1269.3±78.0<0.001416.1±83.6252.9±54.10.001
Subfoveal CT (μm)206.9±57.8186.4±60.60.006275.1±82.5235.3±79.40.001
  • *Data are presented as mean±SD.

  • †p Value using the Wilcoxon signed-rank test.

  • BCVA, best-corrected visual acuity; CMT, central macular thickness; CT, choroidal thickness; logMAR, logarithm of the minimum angle of resolution; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial detachment.